Table 2 Safety summary

From: Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

Participantsa, n (%)

Nivolumab plus ipilimumab (n = 282)

Nivolumab (n = 318)

Durvalumab (n = 317)

AEs

 Any grade

279 (99)

315 (99)

312 (98)

 Grade 3–4

191 (68)

210 (66)

183 (58)

AEs leading to discontinuation

 Any grade

71 (25)

62 (20)

58 (18)

 Grade 3–4

44 (16)

37 (12)

37 (12)

SAEs

 Any grade

155 (55)

156 (49)

136 (43)

 Grade 3–4

103 (36)

112 (35)

90 (28)

TRAEs

 Any grade

269 (95)

307 (96)

305 (96)

 Grade 3–4

161 (57)

172 (54)

154 (49)

Radiotherapy-related AEs

 Any grade

226 (80)

257 (81)

248 (78)

 Grade 3–4

85 (30)

81 (26)

80 (25)

TRAEs leading to discontinuation

 Any grade

61 (22)

50 (16)

40 (13)

 Grade 3–4

40 (14)

30 (9)

24 (8)

Treatment-related SAEs

 Any grade

94 (33)

86 (27)

72 (23)

 Grade 3–4

63 (22)

63 (20)

53 (17)

  1. aAEs per Common Terminology Criteria for AEs version 4.0 and Medical Dictionary for Regulatory Activities version 26.1. Data include events reported between the first dose and 30 days after the last dose of consolidation treatment or at the first dose of retreatment, whichever occurred first.
  2. SAE, serious AE.
Back to article page